Gilead Sciences Inc. (NASDAQ:GILD) – Equities research analysts at Leerink Swann lifted their Q4 2016 earnings per share estimates for Gilead Sciences in a research note issued on Tuesday. Leerink Swann analyst G. Porges now forecasts that the firm will post earnings of $2.98 per share for the quarter, up from their prior forecast of $2.92. Leerink Swann currently has a “Market Perform” rating and a $94.00 price objective on the stock.
A number of other research analysts have also weighed in on GILD. Piper Jaffray Cos. set a $108.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Sunday, August 21st. Jefferies Group reiterated a “hold” rating and issued a $96.00 target price on shares of Gilead Sciences in a report on Wednesday, June 29th. RBC Capital Markets reiterated an “outperform” rating and issued a $105.00 target price (down previously from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday. Finally, Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $93.97 target price for the company in a report on Tuesday, July 26th. Eleven analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $104.34.
Gilead Sciences (NASDAQ:GILD) traded down 0.69% during mid-day trading on Wednesday, reaching $78.70. 3,992,061 shares of the company’s stock were exchanged. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $111.11. The stock has a market cap of $103.86 billion, a price-to-earnings ratio of 6.91 and a beta of 1.06. The company has a 50-day moving average of $79.45 and a 200-day moving average of $85.72.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.15 EPS.
Several hedge funds have recently made changes to their positions in the stock. Webster Bank N. A. boosted its stake in shares of Gilead Sciences by 6.8% in the first quarter. Webster Bank N. A. now owns 26,811 shares of the biopharmaceutical company’s stock worth $2,463,000 after buying an additional 1,707 shares during the period. Searle & CO. boosted its position in shares of Gilead Sciences by 1.5% in the first quarter. Searle & CO. now owns 14,570 shares of the biopharmaceutical company’s stock worth $1,371,000 after buying an additional 220 shares during the last quarter. Bath Savings Trust Co boosted its position in shares of Gilead Sciences by 5.7% in the first quarter. Bath Savings Trust Co now owns 37,715 shares of the biopharmaceutical company’s stock worth $3,464,000 after buying an additional 2,022 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of Gilead Sciences by 13.9% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 22,975 shares of the biopharmaceutical company’s stock worth $2,110,000 after buying an additional 2,796 shares during the last quarter. Finally, Independent Portfolio Consultants Inc. boosted its position in shares of Gilead Sciences by 3.7% in the first quarter. Independent Portfolio Consultants Inc. now owns 21,768 shares of the biopharmaceutical company’s stock worth $2,000,000 after buying an additional 785 shares during the last quarter. Hedge funds and other institutional investors own 77.94% of the company’s stock.
In other news, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $83.12, for a total transaction of $166,240.00. Following the sale, the executive vice president now owns 63,122 shares in the company, valued at approximately $5,246,700.64. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the sale, the executive vice president now owns 132,964 shares in the company, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.